Filspari was Travere Therapeutics’s largest product and service line in fiscal 2025, bringing in $322.01M of $490.73M (66%).
| Product and Service | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Filspari | — | $29.21M | $132.22M | $322.01M | ||||||
| Tiopronin Products | $97.97M | $98.33M | $94.49M | $88.46M | ||||||
| Bile Acid Products | — | — | — | — | ||||||
| Thiola License | — | — | — | — | ||||||
| License & Collaboration Revenue | $11.49M | $17.70M | $6.47M | $80.27M | ||||||
| Total | $109.46M | $145.24M | $233.18M | $490.73M |
Travere Therapeutics brought in $490.73M from its three product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 110.5% from $233.18M in fiscal 2024. Filspari was the largest at $322.01M (65.6%), ahead of Tiopronin Products at $88.46M (18.0%) and License & Collaboration Revenue at $80.27M (16.4%).
Compared with fiscal 2024, License & Collaboration Revenue grew fastest, up 1,141.0% to $80.27M, while Tiopronin Products fell the most, down 6.4% to $88.46M.
Travere Therapeutics began breaking out Filspari in fiscal 2023, when it brought in $29.21M.
Travere Therapeutics (TVTX) reports its revenue by product and service. In fiscal 2025, Filspari was its largest product and service line, bringing in $322.01M (65.6% of the total), followed by Tiopronin Products at $88.46M (18.0%).
Filspari was Travere Therapeutics' largest product and service line in fiscal 2025, bringing in $322.01M, or 65.6% of the $490.73M total across its three product and service lines.
Among Travere Therapeutics' product and service lines that make up at least 2% of revenue, License & Collaboration Revenue grew fastest in fiscal 2025, up 1,141.0% from $6.47M to $80.27M.
Every figure comes from Travere Therapeutics' annual financial filings, as reported. Each line keeps the name Travere Therapeutics gives it, and years follow its fiscal calendar.
Travere Therapeutics' revenue by product and service goes back to fiscal 2015, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.